[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Hagenah GC, Wündisch T, Eckstein E, Zimmermann S, Holst F, Grimm W, Neubauer A, Lohoff M: [Sepsis-like disease in an immunocompromised patient with a travel history to Mallorca]. Internist (Berl); 2007 Jul;48(7):727-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surprisingly, histological examination of the resected colon reveiled the presence of an immunoblastic B-cell lymphoma.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Immunologic Deficiency Syndromes / complications. Leishmania infantum. Leishmaniasis, Visceral / diagnosis. Lymphoma, Large-Cell, Immunoblastic / diagnosis. Pancytopenia / etiology. Sepsis / etiology. Travel
  • [MeSH-minor] Adult. Animals. Azathioprine / adverse effects. Azathioprine / therapeutic use. Biopsy. Bone Marrow / pathology. Colectomy. Colitis, Ulcerative / drug therapy. Colon / pathology. Comorbidity. Desoxycorticosterone / adverse effects. Desoxycorticosterone / therapeutic use. Diagnosis, Differential. Germany. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Male. Spain

  • MedlinePlus Health Information. consumer health - Sepsis.
  • MedlinePlus Health Information. consumer health - Traveler's Health.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1561-77 [16257344.001]
  • [Cites] J Clin Microbiol. 2006 Jul;44(7):2343-7 [16825347.001]
  • [Cites] Internist (Berl). 2006 Aug;47(8):825-8, 830-3 [16819655.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2005 Jul;24(7):471-6 [15997368.001]
  • [Cites] Microbes Infect. 2005 Oct;7(13):1370-5 [16046170.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1995 May-Jun;89(3):273-5 [7660431.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1995 Jan-Feb;89(1):33 [7747301.001]
  • [Cites] Clin Microbiol Rev. 1997 Apr;10(2):298-319 [9105756.001]
  • (PMID = 17541532.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 40GP35YQ49 / Desoxycorticosterone; MRK240IY2L / Azathioprine
  •  go-up   go-down


2. Rodríguez M, Perea J, Ortega I, Turégano F: [Group A beta-hemolytic Streptococcus necrotizing fascitis secondary to muscular effort]. Enferm Infecc Microbiol Clin; 2002 Jan;20(1):42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease Susceptibility. Humans. Imipenem / therapeutic use. Lymphoma, Large-Cell, Immunoblastic / complications. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / surgery. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11820983.001).
  • [ISSN] 0213-005X
  • [Journal-full-title] Enfermedades infecciosas y microbiología clínica
  • [ISO-abbreviation] Enferm. Infecc. Microbiol. Clin.
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 71OTZ9ZE0A / Imipenem
  •  go-up   go-down


3. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol; 2001 Feb 01;19(3):742-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
  • PURPOSE: To assess the feasibility and efficacy of intensive chemotherapy with hematopoietic stem-cell rescue (IC + HCR) in patients with refractory or recurrent primary CNS lymphoma (PCNSL) or intraocular lymphoma (IOL).
  • Before IC, eight patients were in complete remission (CR), four were in partial remission (PR), one had stable disease, and seven had refractory disease.
  • After IC + HCR, 16 patients entered CR, two remained in PR, one had stable disease, and one had disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Central Nervous System Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Busulfan / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Feasibility Studies. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / therapy. Male. Methotrexate / administration & dosage. Middle Aged. Nervous System Diseases / chemically induced. Salvage Therapy. Thiotepa / administration & dosage

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11157026.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Soussain C, Hoang-Xuan K, Levy V: [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]. Bull Cancer; 2004 Feb;91(2):189-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
  • Rescue therapies for relapsing/refractory primary central nervous system lymphoma (PCNSL) and intraocular lymphoma (IOL) remain a challenging problem for clinicians.
  • In 2001, we published encouraging results for 22 patients treated at relapse with a CYVE regimen combining high doses of Ara-C (50 mg/m(2)/d in 12 hours infusion dl through d5; 2 g/m(2)/d d2 through d5) and VP16 (200 mg/m(2)/d d2 through d5), followed by intensive chemotherapy based on high doses of thiotepa (250 mg/m(2)/d d-9 through d-7), busulfan (10 mg/kg total dose d-6 through d-4) and cyclophosphamide (60 mg/kg/d, d-3 and d-2 with hematopoietic cell rescue at d0.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Busulfan / adverse effects. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Etoposide / administration & dosage. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / therapy. Middle Aged. Prognosis. Recurrence. Thiotepa / administration & dosage. Thiotepa / adverse effects

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright John Libbey Eurotext 2003.
  • (PMID = 15047459.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


5. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM: Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma; 2005 Dec;46(12):1721-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
  • Non-Hodgkin's lymphoma of the paranasal sinus is an uncommon presentation of extranodal lymphoma.
  • In British Columbia (population 4 million), a central database for lymphomas has allowed us to accurately track cases of paranasal sinus lymphoma diagnosed since 1980.
  • A retrospective review was performed on the 44 patients who presented with primary paranasal sinus lymphoma (stage I or II) between 1980 and 1999.
  • Complete diagnostic and follow-up data including stage, treatment, response rates, sites of relapse and survival data were available for all patients.
  • The types of lymphoma found were: diffuse large B cell (including immunoblastic), n = 37 (84%); T/NK nasal type, n = 3 (8%); peripheral T cell, not otherwise classified, n = 2 (4%); and others, n = 2 (4%).
  • Beginning in May 1985, intrathecal chemotherapy was added to our standard treatment plan of multi-agent chemotherapy and local irradiation.
  • Primary paranasal sinus lymphoma is an uncommon presentation of lymphoma that carries the potential risk of spreading to the leptomeninges.
  • [MeSH-major] Chemoprevention. Lymphoma, Non-Hodgkin / physiopathology. Paranasal Sinus Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263574.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Brousse C, Baumelou E, Morel P: Primary lymphoma of bone: a prospective study of 28 cases. Joint Bone Spine; 2000;67(5):446-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of bone: a prospective study of 28 cases.
  • PURPOSE: To conduct a prospective study of primary lymphoma of bone (PLB) comparatively with extraskeletal non-Hodgkin's lymphomas (ESNHLs) and secondary lymphoma of bone (SLB).
  • PATIENTS AND METHODS: The 28 cases of PLB, 2932 cases of ESNHL, and 219 cases of SLB included between April 1, 1993, and October 1, 1997, in a treatment protocol for NHL developed by the Adult Lymphoma Study Group, were studied prospectively.
  • The Ann Arbor stage distribution (I-II/III-IV) was as follows: 54%/46% in the PLB group, 50%/50% in the ESNHL group, and 20%/80% in the SLB group.
  • In the PLB group, 54% of patients had diffuse large cell tumors and 11% diffuse mixed tumors; in the ESNHL group, 39% had diffuse large cell, 13% diffuse mixed, and 8% diffuse immunoblastic tumors; and in the SLB group, 45% had diffuse large cell, 10% diffuse mixed, and 12% diffuse immunoblastic tumors.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Surveys and Questionnaires. Survival Rate. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11143912.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; LNH 87 protocol
  •  go-up   go-down


7. Skugor ND, Perić Z, Vrhovac R, Radić-Kristo D, Kardum-Skelin I, Jaksić B: Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma. Coll Antropol; 2010 Mar;34(1):241-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
  • Relatively few cases of Epstein-Barr (EBV)-positive B-cell lymphomas arising in patients with angioimmunoblastic T-cell lymphoma (AITL) have been reported.
  • We report a case of AITL in which diffuse large B-cell lymphoma arose 13 months after the initial diagnosis of AITL.
  • The patient initially recieved FED chemotherapy (fludarabine, cyclophosphamide, dexamethasone) followed by elective autologous hematopoietic stem cell transplantation.
  • The FNAC of the enlarged cervical lymph nodes was performed again, but this time the smears were composed of polymorphous population of lymphocytes with the predomination of large cells, CD20+ on immunocytochemical stains.
  • Reduced intensity allogeneic stem cell transplantation performed thereafter, resulted in complete remission of the disease.
  • AITL is a rare lymphoproliferative disorder in which the neoplastic T-cells represent the minority of the lymph node cell population and almost all cases harbor EBV-infected B-cells.
  • Various authors postulated that immunodeficiency in AITL patients together with immunosuppressive effects of cytotoxic drugs, may be responsible for EBV-induced proliferation of latently or newly EBV-infected B-cells with eventual clonal selection and progression to aggressive B-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Fine-Needle. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / pathology. Female. Humans. Immunophenotyping. Neoplasm Recurrence, Local / pathology. Prednisone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432757.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Yin WH, Zhang HY, Li XF, Ma Y: [Drug-induced lymphadenitis]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):192-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug-induced lymphadenitis].
  • [MeSH-major] Drug Hypersensitivity / etiology. Drug Hypersensitivity / pathology. Lymphadenitis / chemically induced. Lymphadenitis / pathology. Sulfasalazine / adverse effects
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antigens, CD3 / metabolism. Antigens, CD30 / metabolism. Colitis, Ulcerative / drug therapy. Diagnosis, Differential. Female. Gastrointestinal Agents / adverse effects. Gastrointestinal Agents / therapeutic use. Humans. Immunoblastic Lymphadenopathy / metabolism. Immunoblastic Lymphadenopathy / pathology. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / pathology. Receptors, Complement 3d / metabolism

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. SULFASALAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450768.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / Gastrointestinal Agents; 0 / Receptors, Complement 3d; 3XC8GUZ6CB / Sulfasalazine
  •  go-up   go-down


9. Ladrière M, Bibes B, Rabaud C, Delaby P, May T, Canton P: [Varicella zoster virus infection after bone marrow transplant. Unusual presentation and importance of prevention]. Presse Med; 2001 Jul 7-13;30(23):1151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Infection par le virus varicelle-zona après greffe de moelle osseuse. Présentations inhabituelles et intérêt de la prophylaxie.
  • The second patient was a 42-year-old woman treated with autologous bone marrow transplantation for lymphoma.
  • [MeSH-major] Bone Marrow Transplantation. Herpes Zoster / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Lymphoma, Large-Cell, Immunoblastic / therapy. Myelitis, Transverse / diagnosis. Opportunistic Infections / diagnosis. Pancreatitis / diagnosis
  • [MeSH-minor] Adult. Antiviral Agents / administration & dosage. Antiviral Agents / adverse effects. Drug Therapy, Combination. Fatal Outcome. Female. Graft vs Host Disease / drug therapy. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Lymphocyte Depletion. Magnetic Resonance Imaging. Male. Spinal Cord / pathology. Tomography, X-Ray Computed


10. Dawson MA, Schwarer AP, McLean C, Oei P, Campbell LJ, Wright E, Shortt J, Street AM: AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haematologica; 2007 Jan;92(1):e11-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.
  • Plasmablastic lymphoma is an AIDS related lymphoma that continues to have a poor prognosis despite significant advances in the management of HIV and lymphoproliferative diseases.
  • To date molecular abnormalities have not been described in plasmablastic lymphoma, and its aggressive clinical behaviour has been difficult to understand.
  • We describe the first reported cytogenetic abnormality in plasmablastic lymphoma, an IgH/MYC translocation.
  • It is also the first description of autologous stem cell transplantation in a patient with severe haemophilia A.
  • [MeSH-major] Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 8 / ultrastructure. Genes, myc. Gingival Neoplasms / genetics. Hemophilia A / complications. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Large-Cell, Immunoblastic / genetics. Peripheral Blood Stem Cell Transplantation. Translocation, Genetic
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / complications. Fatal Outcome. Humans. Male. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Transplantation, Autologous. Vincristine / administration & dosage


11. Sawka CA, Shepherd FA, Franssen E, Brandwein J, Dotten DA, Routy JP, Walker IR, St-Louis J, Taylor M, Arts K, Crump M, Foote M: A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. Biotechnol Annu Rev; 2005;11:381-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) remains an important complication of associated HIV infection despite advances in antiretroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined.
  • Forty-seven patients were enrolled, most with diffuse large-cell or immunoblastic NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Bleomycin / adverse effects. Bleomycin / therapeutic use. CD4 Lymphocyte Count. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Injections, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Prospective Studies. Recombinant Proteins. Survival Analysis. Treatment Outcome. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216784.001).
  • [ISSN] 1387-2656
  • [Journal-full-title] Biotechnology annual review
  • [ISO-abbreviation] Biotechnol Annu Rev
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


12. Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA: Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer; 2001 Jul 15;92(2):207-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
  • BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.
  • METHODS: Eligibility criteria included histologically documented, diffuse small cleaved, diffuse mixed, diffuse large cell, or immunoblastic lymphoma, Stage III--IV or bulky Stage II disease, and an ECOG performance status of 0--1.
  • The MTD in both studies was defined as the dose at which 50% of patients had 1) Grade 4 neutropenia or thrombocytopenia lasting 7 days or more, or 2) Grade 3--4 hemorrhage or nonhematologic toxicity (excluding alopecia, nausea, and emesis), or 3) were prevented from receiving 100% of drug on Day 22.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / prevention & control. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11466671.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA45418
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


13. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, Katlama C, Lazzarin A, Skinhøj P, Barton SE, EuroSIDA Study Group: Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood; 2001 Dec 1;98(12):3406-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy.
  • This study was designed to assess the influence of highly active antiretroviral therapy (HAART) on non-Hodgkin lymphoma (NHL) among patients infected with human immunodeficiency virus (HIV).
  • Within EuroSIDA, a multicenter observational cohort of more than 8500 patients from across Europe, the incidences of NHL and subtypes (Burkitt, immunoblastic, primary brain lymphoma [PBL], and other/unknown histology) were determined according to calendar time of follow-up, and for those who initiated HAART (> or =3 drugs) also time on HAART.
  • In an adjusted Cox model for patients on HAART, the latest CD4 cell count and plasma viral load were both significantly associated with diagnosis of NHL; the relative hazard was 1.39 (range, 1.14-1.69) per 50% lower CD4 cell count, and 1.51 (range, 1.21-1.88) per 1 log higher plasma viral load.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Brain Neoplasms / complications. Brain Neoplasms / epidemiology. Burkitt Lymphoma / complications. Burkitt Lymphoma / epidemiology. CD4 Lymphocyte Count. Cohort Studies. Female. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Prospective Studies


14. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN: Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist; 2010;15(3):293-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a variant of diffuse large B-cell lymphoma commonly seen in the oral cavity of HIV-infected individuals.
  • Further research is needed to improve responses using novel therapeutic agents and strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / virology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(3):194 [10942339.001]
  • [Cites] J Hematol Oncol. 2009;2:47 [19909553.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):423-6 [11999580.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1582-4 [12824797.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]
  • [Cites] Haematologica. 2007 Jan;92(1):e11-2 [17405744.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1361-4 [17577503.001]
  • [Cites] Am J Hematol. 2007 Aug;82(8):761-5 [17094093.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Oral Dis. 2009 Jan;15(1):38-45 [18939960.001]
  • [Cites] Intern Med. 2009;48(7):559-62 [19336959.001]
  • [Cites] Eur J Haematol. 2009 Jun;82(6):490-2 [19220417.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6069-76 [19380866.001]
  • [Cites] AIDS. 2009 Sep 24;23(15):2029-37 [19531926.001]
  • [Cites] Am J Clin Pathol. 2009 Oct;132(4):597-605 [19762538.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • (PMID = 20167839.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC3227958
  •  go-up   go-down


15. Boulanger E, Agbalika F, Maarek O, Daniel MT, Grollet L, Molina JM, Sigaux F, Oksenhendler E: A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J; 2001;2(3):172-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
  • INTRODUCTION: Primary effusion lymphoma is a rare type of B-cell lymphoproliferative disorder which is mainly observed in patients with HIV infection.
  • Lymphomatous cells bridge features of immunoblastic and anaplastic cells with a non-B non-T phenotype and are characterized by the presence of the human herpesvirus 8 genome.
  • PATIENTS AND METHODS: : Twelve HIV-infected patients with serous effusions containing large HHV8(+) lymphomatous cells were extensively evaluated to disclose associated visceral involvement.
  • RESULTS: Extraserous localizations of lymphoma were present in six cases (50%): mediastinal (n = 2), mesenteric (n = 2), pancreatic (n = 1), and bone marrow involvement (n = 1).
  • CONCLUSION: The clinical and molecular pattern, as well as the response to therapy suggest that primary effusion lymphoma represents an heterogenous type of virus-induced B-cell lymphoproliferative disorder, sharing pathophysiological features with that induced by the Epstein-Barr virus and occurring in immunocompromised patients.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11920242.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8J337D1HZY / Cytosine; 8N3DW7272P / Cyclophosphamide; JIL713Q00N / cidofovir; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 37
  •  go-up   go-down


16. Tulpule A, Sherrod A, Dharmapala D, Young LL, Espina BM, Sanchez MN, Gill PS, Levine AM: Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res; 2002 Feb;26(2):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • P-glycoprotein is a product of the multidrug resistance (MDR-1) gene.
  • In non-Hodgkin's lymphoma, less than 20% of untreated de novo lymphomas express MDR-1 compared with approximately 50% after failure of chemotherapy.
  • We wished to study the expression of MDR-1 in AIDS-related non-Hodgkin's lymphoma (AIDS-NHL).
  • MDR-1 expression was correlated with patient demographics, lymphoma characteristics, response to chemotherapy, and survival.
  • Pathologic types consisted of diffuse large cell in 13 (26%), immunoblastic in 13 (26%), small non-cleaved in 22 (44%), and high grade not otherwise specified in two (4%).
  • The majority of patients (76%) had stage III/IV disease.
  • Pre-treatment lymphoma tissues from 33 patients (66%) stained positively for MDR-1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / metabolism. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Lymphoma, AIDS-Related / metabolism. Neoplasm Proteins / biosynthesis. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / mortality. Adult. Anti-HIV Agents / therapeutic use. Bleomycin / administration & dosage. Bleomycin / metabolism. Bleomycin / pharmacology. Cyclophosphamide / administration & dosage. Cyclophosphamide / metabolism. Cyclophosphamide / pharmacology. Dexamethasone / administration & dosage. Dexamethasone / metabolism. Dexamethasone / pharmacology. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / metabolism. Doxorubicin / pharmacology. Female. Humans. Leucovorin / administration & dosage. Leucovorin / metabolism. Leucovorin / pharmacology. Male. Methotrexate / administration & dosage. Methotrexate / metabolism. Methotrexate / pharmacology. Middle Aged. Prednisone / administration & dosage. Prednisone / metabolism. Prednisone / pharmacology. Remission Induction. Retrospective Studies. Survival Analysis. Vincristine / administration & dosage. Vincristine / metabolism. Vincristine / pharmacology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11755462.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; M-BACOD protocol
  •  go-up   go-down


17. Portlock CS, Qin J, Schaindlin P, Roistacher N, Myers J, Filippa D, Louie D, Zelenetz AD, O'Brien JP, Moskowitz C, Norton L, Yahalom J, Straus DJ, Bertino JR: The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol; 2004 Oct;15(10):1495-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with aggressive non-Hodgkin's lymphomas (working formulation: intermediate grade or immunoblastic), bulky stage I and stages II-IV, were eligible.
  • When the diffuse large cell lymphoma histologies were grouped according to the International Prognostic Index (IPI), complete remission and OS in the low-intermediate (LI), and high-intermediate (HI) risk groups were improved by 5%-15% compared with historical CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15367410.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA05826; United States / NCI NIH HHS / CA / R01 CA61522
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


18. Salven P, Orpana A, Teerenhovi L, Joensuu H: Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood; 2000 Dec 1;96(12):3712-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.
  • The combined effect of S-VEGF and S-bFGF on the survival of 200 patients with non-Hodgkin lymphoma (NHL) was studied.
  • Simultaneous elevation of S-VEGF and S-bFGF was associated with poor survival in different grades of lymphomas and in the largest histologic subgroup, the large-cell diffuse and immunoblastic lymphomas.
  • [MeSH-major] Endothelial Growth Factors / blood. Fibroblast Growth Factor 2 / blood. Lymphokines / blood. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers / blood. Cohort Studies. Drug Resistance. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Middle Aged. Multivariate Analysis. Prognosis. Survival Analysis. Survival Rate. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11090051.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


19. Xu RH, Jiang WQ, Li YH, Lin TY, Huang HQ, Xia ZJ, Sun XF, He YJ, Guan ZZ: [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases]. Zhonghua Yi Xue Za Zhi; 2003 Feb 10;83(3):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases].
  • OBJECTIVE: To analyze the curative effect of aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis.
  • METHODS: The curative effects of aggressive non-Hodgkin's lymphoma which were diagnosed as diffuse small cleaved (E), diffuse mixed (F), diffuse large cell (G) or diffuse immunoblastic lymphoma (H) pathologically and certified as B cell lymphoma immunohistologically and treated with CHOP or other ADM-containing regimens for at least 4 cycles from 1993 to 1997 were analyzed.
  • 131 (68.9%) patients achieved CR, and 47 (24.6%) achieved PR.
  • CONCLUSION: The treatment with CHOP as its main component has a beneficial effect on aggressive B cell lymphoma in low risk group, but is less effective for the low-intermediate, high-intermediate, and high risk.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Follow-Up Studies. Humans. Infant. Middle Aged. Prednisone / administration & dosage. Prognosis. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12812658.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. Oksenhendler E, Gerard L, Dubreuil ML, Levy Y, Matheron S, Cazals-Hatem D, Chevret S, Clauvel JP: Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma; 2000 Sep;39(1-2):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
  • The purpose of the study was to evaluate the safety and long-term efficacy of an intensive chemotherapy regimen associated with G-CSF in HIV-associated non-Hodgkin's lymphoma (NHL).
  • The median CD4 cell count was 276 x 10(6)/l.
  • Nineteen tumors were of the Burkitt's type, 23 were large cells, 7 immunoblastic, and 3 anaplastic.
  • Twenty-five patients had stage IV disease (bone marrow involvement in 7, and central nervous system in 9).
  • In conclusion, it seems that in HIV-infected patients with NHL and a CD4 cell count above 100 x 10(6)/l, high complete remission rate and prolonged survival can be achieved with the intensive LNHIV-91 regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Adult. Bleomycin / administration & dosage. Bleomycin / toxicity. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Drug Evaluation. Etoposide / administration & dosage. Etoposide / toxicity. Female. Follow-Up Studies. Hospitalization. Humans. Male. Methotrexate / administration & dosage. Methotrexate / toxicity. Middle Aged. Prednisone / administration & dosage. Prednisone / toxicity. Recurrence. Survival Rate. Treatment Outcome. Vindesine / administration & dosage. Vindesine / toxicity

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975387.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol
  •  go-up   go-down


21. Villela L, López-Guillermo A, Montoto S, Rives S, Bosch F, Perales M, Ferrer A, Esteve J, Colomo L, Campo E, Montserrat E: Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer; 2001 Apr 15;91(8):1557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens.
  • BACKGROUND: The current study was conducted to analyze the outcome and prognostic factors of patients with diffuse large B-cell lymphoma (DLCL) who did not achieve a complete response (CR) to first-line treatment.
  • The main variables predicting early death were a poor PS, age > 60 years, and an immunoblastic DLCL subtype.
  • The inclusion of these patients in experimental trials is limited due to their tendency to be of an older age and to have a poor general status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Health Status. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11301405.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement